Outcomes of long‐term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review
Haemophilia2022Vol. 28(3), pp. 373–387
Citations Over TimeTop 13% of 2022 papers
Abdallah El Alayli, Romina Brignardello Petersen, Nedaa Husainat, Mohamad A. Kalot, Yazan Aljabiri, Hani Turkmani, Alec Britt, Hussein El‐Khechen, Shaneela Shahid, John Roller, Shahrzad Motaghi, Razan Mansour, Alberto Tosetto, Rezan A. Kadir, Michael Laffan, Angela C. Weyand, Frank W.G. Leebeek, Alice Arapshian, Peter A. Kouides, Paula James, Nathan T. Connell, Veronica H. Flood, Reem A. Mustafa
Abstract
VWD prophylaxis treatment seems to reduce the risk of spontaneous bleeding, epistaxis, and hospitalizations. More RCTs should be conducted to increase the certainty in these benefits.
Related Papers
- → von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy(2013)163 cited
- → von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy(2013)72 cited
- → Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device‐induced acquired von Willebrand syndrome(2018)11 cited
- European Clinical, Laboratory and Molecular (2020 ECLM) Diagnostic Work-Up and Classification of Von Willebrand Disease from the Perspectives of Clinicians and Scientists(2019)
- → Functional Assessment of VWD Type 2N Variants Using Mammalian Cell Displayed Surface-Tethered Von Willebrand Factor(2023)